Mesenchymal Stem Cell-Derived Extracellular Vesicles as Idiopathic Pulmonary Fibrosis Microenvironment Targeted Delivery
Open Access
Abstract
Idiopathic pulmonary fibrosis (IPF) affects an increasing number of people globally, yet treatment options remain limited. At present, conventional treatments depending on drug therapy do not show an ideal effect in reversing the lung damage or extending the lives of IPF patients. In recent years, more and more attention has focused on extracellular vesicles (EVs) which show extraordinary therapeutic effects in inflammation, fibrosis disease, and tissue damage repair in many kinds of disease therapy. More importantly, EVs can be modified or used as a drug or cytokine delivery tool, targeting injury sites to enhance treatment efficiency. In light of this, the treatment strategy of mesenchymal stem cell-extracellular vesicles (MSC-EVs) targeting the pulmonary microenvironment for IPF provides a new idea for the treatment of IPF. In this review, we summarized the inflammation, immune dysregulation, and extracellular matrix microenvironment (ECM) disorders in the IPF microenvironment in order to reveal the treatment strategy of MSC-EVs targeting the pulmonary microenvironment for IPF.Keywords
Funding Information
- National Natural Science Foundation of China (81971878, BLB19J006, 20JCQNJC01260, 2021YFC3002202)
- Opening Project of Military Logistics (81971878, BLB19J006, 20JCQNJC01260, 2021YFC3002202)
- Tianjin Natural Science Foundation (81971878, BLB19J006, 20JCQNJC01260, 2021YFC3002202)
- National Key Research and Development Program of China (81971878, BLB19J006, 20JCQNJC01260, 2021YFC3002202)
This publication has 177 references indexed in Scilit:
- Macrophages and fibrosis: How resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repairBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosisJournal of Inflammation Research, 2013
- IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression studyImmunogenetics, 2012
- The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosisLaboratory Investigation, 2011
- Integrating mechanisms of pulmonary fibrosisJournal of Experimental Medicine, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Alternative Activation of Macrophages: Mechanism and FunctionsImmunity, 2010
- Role of Particle Size in Phagocytosis of Polymeric MicrospheresPharmaceutical Research, 2008
- Acute Exacerbations of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Alternative activation of macrophagesNature Reviews Immunology, 2003